Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement-regulatory proteins in ovarian malignancies

L Bjørge1, J Hakulinen, T Wahlström

  • 1Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland.

International Journal of Cancer
|January 6, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Gynecologic oncology·2024
Same author

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.

Molecular immunology·2022
Same author

Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1.

Nature communications·2021
Same author

Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.

The British journal of dermatology·2019
Same journal

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy.

International journal of cancer·2026
Same journal

Leveraging Minimal Variables for Maximal Screening Yield: A Global Equity Perspective on Colorectal Cancer Risk Stratification.

International journal of cancer·2026
Same journal

Bispecific Antibody-Based Combination Therapies for B-Cell Lymphomas: Current Evidence and Future Perspectives.

International journal of cancer·2026
Same journal

Cancer Survival for Selected Cancers in Türkiye (2008-2017): A Population-Based Study.

International journal of cancer·2026
Same journal

Cardiovascular-Kidney-Metabolic Syndrome, Healthy Lifestyles, and Risk of Cancer Incidence and Mortality: A Prospective Cohort Study.

International journal of cancer·2026
Same journal

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.

International journal of cancer·2026
See all related articles

Ovarian cancer cells resist complement (C) attack using regulators like MCP (CD46) and protectin (CD59). Targeting these C regulators may improve MAb immunotherapy effectiveness for ovarian cancer.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Ovarian cancer is a target for MAb adjuvant immunotherapy.
  • Antibody-mediated immunotherapy often relies on complement (C) activation for cancer cell destruction.
  • Understanding how ovarian tumors evade C attack is crucial for effective immunotherapy.

Purpose of the Study:

  • To investigate the expression and role of complement regulatory proteins on ovarian tumor cells.
  • To determine if these regulators contribute to tumor resistance against C-mediated lysis.
  • To assess the implications for MAb-based immunotherapy strategies.

Main Methods:

  • Analysis of complement regulator expression (MCP/CD46, DAF/CD55, CD59) in human ovarian tumors and cell lines.
  • Assessment of protein localization and correlation with mRNA transcripts.

Related Experiment Videos

  • Evaluation of cell sensitivity to C-mediated lysis and the effect of CD59 neutralization.

    • Main Results:

    • Strong expression of MCP (CD46) and protectin (CD59) was found in all examined ovarian tumors.
    • Decay-accelerating factor (DAF; CD55) expression was heterogeneous.
    • Neutralizing CD59 significantly enhanced C-mediated killing, and low regulator expression correlated with high sensitivity to lysis.

    Conclusions:

    • Complement regulators on ovarian cancer cells represent a potential tumor escape mechanism.
    • Expression levels of these regulators are critical parameters for evaluating MAb therapy efficacy.
    • Targeting complement regulators could enhance MAb immunotherapy outcomes in ovarian cancer.